Article Menu

Export Article

More by Authors Links

Article Data

  • Views 2296
  • Dowloads 133

Case Reports

Open Access

Osteosarcoma appearing in the uterus as malignant mixed Müllerian tumor

  • Liu Jin1
  • Yang Xi2
  • Zhang Wenyuan1
  • Ping Jinliang1
  • Zhong Liping1
  • Han Shuwen1,*,

1Huzhou Central Hospital, Huzhou, Zhejiang, Huzhou, China

2Oncology department, Wannan Medical College, Wuhu, Anhui , China

DOI: 10.12892/ejgo3991.2018 Vol.39,Issue 3,June 2018 pp.488-492

Published: 10 June 2018

*Corresponding Author(s): Han Shuwen E-mail: huwenHan985@163.com

PDF (1.69 MB) View Full-text

Abstract

Few cases of osteosarcoma appearing in the uterus as malignant mixed Müllerian tumor have been published in the literature to the authors’ knowledge. They report a 59-year-old postmenopausal female that underwent total abdominal hysterectomy and bilateral adnexectomy and bilateral pelvic cavity and abdominal periaortic lymphadenectomy because of numerous irregular mass in the uterus. The histopathological diagnosis which was confirmed by immunohistochemical study was osteosarcoma appearing in the uterus as malignant mixed Müllerian tumor. Then for cycles of chemotherapeutic regimens (paclitaxel plus carboplatin, 21 days as one cycle) was started at 16 days after surgery. This was a rare case of osteosarcoma appearing in the uterine as malignant mixed Müllerian tumor.

Keywords

Osteosarcoma; Malignant mixed Müllerian tumor; Uterine sarcoma.

Cite and Share

Liu Jin,Yang Xi,Zhang Wenyuan,Ping Jinliang,Zhong Liping,Han Shuwen. Osteosarcoma appearing in the uterus as malignant mixed Müllerian tumor. European Journal of Gynaecological Oncology. 2018. 39(3);488-492.

URL:

https://www.ejgo.net/articles/10.12892/ejgo3991.2018

References

[1] Duncan M.E., Seagroatt V., Goldacre M.J.: “Cancer of the body of the uterus: trends in mortality and incidence in England, 1985-2008”. BJOG, 2012, 119, 333.

[2] Hayata E., Seto K., Haga K., Kitazawa T., Matsumoto K., Morita M., et al.: “Cost of illness of the cervical cancer of the uterus in Japan—a time trend and future projections”. BMC Health Serv. Res., 2015, 15, 104.

[3] Machii R., Saika K.: “Time trends in uterus cancer mortality between 1955 and 2008 in Japan, U.S.A. and Europe based on the WHO Mortality Database”. Jpn. J. Clin. Oncol., 2011, 41, 1313.

[4] Zhang M.J., Katanoda K.: ‘Comparison of time trends in uterus cancer and cervix uteri cancer mortality (1990-2006) in the world, from the WHO Mortality Database”. Jpn. J. Clin. Oncol., 2010, 40, 98.

[5] Monappa V., Kudva R., Hasan R.: “Uterine malignant mixed müllerian tumor camouflaging as pelvic sarcoma”. J. Cancer Res. Ther., 2015, 11, 997.

[6] Ding L., Congwei L., Bei Q., Tao Y., Ruiguo W., Heze Y., et al.: “mTOR: an attractive therapeutic target for osteosarcoma?” Oncotarget, 2016, 7, 50805

[7] Kurshumliu F., Rung-Hansen H., Skovlund V.R., Gashi-Luci L., Horn T.: “Primary malignant mixed müllerian tumor of the peritoneum a case report with review of the literature”. World J. Surg. Oncol., 2011, 9, 17.

[8] King M.E., Kramer E.E.: “Malignant Mullerian mixed tumors of the uterus: a study of 21 cases”. Cancer, 1980, 45, 188.

[9] Kanthan R., Senger J.L.: “Uterine carcinosarcomas (malignant mixed müllerian tumours): a review with special emphasis on the controversies in management”. Obstet. Gynecol. Int., 2011, 2011, 470795.

[10] Singh R.: “Review literature on uterine carcinosarcoma”. J. Cancer Res. Ther., 2014, 10, 461.

[11] Monappa V., Kudva R., Hasan R.: “Uterine malignant mixed müllerian tumor camouflaging as pelvic sarcoma”. J. Cancer Res. Ther., 2015, 11, 997.

[12] Gonzalez Bosquet J., Terstriep S.A., Cliby W.A., Brown-Jones M., Kaur J.S., Podratz K.C., et al.: “The impact of multi-modal therapy on survival for uterine carcinosarcomas”. Gynecol. Oncol., 2010, 116, 419.

[13] Burghaus S., Halmen S., Gass P., Mehlhorn G., Schrauder M.G., Lux M.P., et al.: “Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor”. Arch. Gynecol. Obstet., 2016, 294, 343.

[14] Al Asiri M., Tunio M.A., Bayoumi Y., Mohamed R., Al Saeed E., Al Hadab A., Al Amro A.: “Five years treatment outcomes of postoperative radiotherapy in saudi women with uterine cancers: single institutional experience”. Gulf J. Oncolog., 2014, 1, 32.

[15] Potikul C., Tangjitgamol S., Khunnarong J., Srijaipracharoen S., Thavaramara T., Pataradool K.: “Uterine sarcoma: clinical presentation, treatment and survival outcomes in Thailand”. Asian Pac. J.Cancer Prev., 2016, 17, 1759.

[16] Mok J.E., Kim Y.M., Jung M.H., Kim K.R., Kim D.Y., Kim J.H., et al.: “Malignant mixed müllerian tumors of the ovary: experience with cytoreductive surgery and platinum-based combination chemotherapy”. Int. J. Gynecol. Cancer, 2006, 16, 101.

[17] Ko M.L., Jeng C.J., Huang S.H., Shen J., Tzeng C.R., Chen S.C.: “Primary peritoneal carcinosarcoma (malignant mixed mullerian tumor): Report of a case with five-year disease free survival after surgery and chemoradiation and a review of literature”. Acta Oncol., 2005, 44, 756.

[18] Peters W.A., Rivkin S.E., Smith M.R., Tesh D.E.: “Cisplatin and adriamycin combination chemotherapy for uterine stromal sarcomas andmixed mesodermal tumors”. Gynecol. Oncol., 1989, 34, 323.

[19] Kapur S., Miles L.: “Primary malignant mixed müllerian mesodermal tumor mimicking a rectosigmoid carcinoma: a case report and review of the literature”. Case Rep. Oncol. Med., 2014, 2014, 948908

Submission Turnaround Time

Top